High versus standard alkali supplementation in kidney disease

Not Applicable

Completed

• Conditions: Health Condition 1: N189- Chronic kidney disease, unspecified

• Registration Number: CTRI/2020/08/027100
• Lead Sponsor: Jawaharlal Institute of postgraduate Medical Education Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-06-22
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 128

Inclusion Criteria

1. All prevalent adult CKD stages 3b, 4 and 5D patients with a minimum follow-up duration of 6 months in Nephrology OPD.

2. Serum bicarbonate (venous) levels below 22meq/L without bicarbonate supplementation.

3. Stable kidney function (defined as eGFR fluctuation of less than 2ml/min/1.73m2 in the preceding 3 months)

4. 24-hour urine protein excretion less than 1g.

Exclusion Criteria

1. Diagnosis of congestive heart failure with New York heart association (NYHA) class 3 or 4 symptoms

2. History of diabetes or fasting plasma glucose >=126mg/dL and/or post prandial plasma glucose >= 200mg/dL and/or glycosylated hemoglobin (HbA1c) >= 6.5

3. Use of four or more antihypertensives for blood pressure control

4. Clinical evidence of volume overload/hypocalcemia/hypercapnea

5. Serum potassium <3meq/L or >=5.5meq/L

6. Serum creatinine <2 mg/dL

7. Decompensated chronic liver disease

8. Kidney transplant recipient

9. Receiving Immunosuppressive drug therapy

10. Active pregnancy

11. Expected to be initiated on dialysis in the next 6 months as assessed by the treating physician.

12. Those who had acute kidney injury (according to KDIGO criteria) in the preceding 3 months.

13. Cystic Kidney disease

14. Obstructive uropathy

Study & Design

• Study Type: Interventional
• Study Design: Not specified